MBX Biosciences raised $63.5 million in a Series C funding round, two years after closing a $115 million Series B.
The biotech, which is focusing on peptide therapies for endocrine and metabolic disorders, now has cash runway into 2026.
It is expecting several readouts before then, including a Phase 1 study in post-bariatric hypoglycemia, with topline data expected in the fourth quarter of this year. It also has a Phase 2 trial of a parathyroid hormone peptide prodrug in hypoparathyroidism, with data expected in the third quarter of 2025.
MBX has a dual GLP-1/GIP agonist in the preclinical stage.
Deep Track Capital led the Series C, with participation from other investors including Driehaus Capital Management, Frazier Life Sciences, OrbiMed and Wellington Management, among others.
MBX brought on a CMO in June, appointing Salomon Azoulay to the role. Azoulay was CMO at Roivant Sciences and Sumitovant Biopharma, and worked at Pfizer as CMO of Pfizer Essential Health.